Cardiovascular System and the Lungs

22 Nov 2026 12:30 12:45
Lalitha Pereirasamy Speaker Malaysia
COPD and cardiovascular disease (CVD) frequently coexist and amplify each other, yet are usually managed separately. They share risk factors such as smoking, ageing and air pollution. Around half of COPD deaths are cardiovascular, and 7–30% of patients with acute myocardial infarction (AMI) have COPD. This presentation brings together recent reviews, a 24-study systematic review, and key cohort and trial data on the mechanisms linking COPD and CVD. It focuses on systemic inflammation and shared biomarkers. COPD confers a risk of major adverse cardiovascular events comparable to diabetes (adjusted HR 1.50 vs 1.41). It nearly triples heart failure risk, with the greatest excess in younger patients. The continuum begins early: low or declining FEV₁, even within normal limits, predicts heart failure, atrial fibrillation and stroke. Five bridges link the organs: systemic inflammation, hypoxaemia, pulmonary vascular remodelling, hyperinflation and autonomic dysfunction. Lung injury activates NF-κB and the NLRP3 inflammasome. IL-1β, IL-6, IL-8 and TNF-α then spill into the circulation, driving endothelial dysfunction, platelet activation and plaque instability. Exacerbations act as a “second hit”: cardiovascular event risk rises 22-fold during severe exacerbations, and AMI risk is eightfold in the first three days. IL-1 blockade is a promising shared target but remains untested in patients with both conditions. Conclusion :NT-proBNP, troponin, coronary artery calcium on chest CT and spirometry are ready for routine use. CRP, fibrinogen, neutrophil-to-lymphocyte ratio and heart rate variability are useful adjuncts. Every exacerbation should be treated as a cardiovascular risk window, with integrated pulmonology–cardiology care.